AbbVie Inc (ABBV NYSE) stock market data APIs
$218.1964
-2.26(-1%)
as of November 5, 2025
Try our APIs with
free plan!
AbbVie Inc Financial Data Overview
Price chart is built with
Anychart
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Prev. Close
218.1964
Open
215.9321
High
219.5431
Low
212.3621
52 wk Range
158.2757-243.0577
Market Cap
381 382 M
P/E Ratio
161.1119
Shares Outstanding
1 767 M
Revenue
59 644 M
EPS
1.86
Dividends (Yield)
0.0309
Beta
0.352
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with AbbVie Inc (top by weight)
Ticker
100-day Price Change
Weight
HDLB.US
ETRACS Monthly Pay 2xLeveraged US High Dividend Low Volatility ETN Series B
-0.43
(-2.81%)
9.80
SXLV.AS
SSgA SPDR ETFs Europe II Public Limited Company - SPDR S&P U.S. Health Care Select Sector UCITS ETF
2.97
(8.27%)
8.08
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get AbbVie Inc data using free add-ons & libraries
Get AbbVie Inc Fundamental Data
AbbVie Inc Fundamental data includes:
- Net Revenue: 59 644 M
- EBITDA: 28 500 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: 3.27
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
AbbVie Inc News
New
Choroidal Neovascularization Market to Witness Accelerated Growth Throughout the Forecast Period (2025–2034) Due to Advancement in Anti-VEGF Therapies | DelveInsight
New York, USA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Choroidal Neovascularization Market to Witness Accelerated Growth Throughout the Forecast Period (2025–2034) Due to Advancement in Anti-VEGF Therap...
Choroidal Neovascularization Market to Witness Accelerated Growth Throughout the Forecast Period (2025–2034) Due to Advancement in Anti-VEGF Therapies | DelveInsight
DelveInsight Business Research LLP The choroidal neovascularization therapeutics market is expected to further increase due to major drivers, including the rising prevalence of the population, techno...
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...
GSK, Amgen and AstraZeneca Lead the Pack in Trinity’s 2025 Digital Marketing Competency Report
WALTHAM, Mass., November 05, 2025--(BUSINESS WIRE)--Trinity, a leader in global life sciences commercialization, today announced the release of its 5th Annual TGaS Digital Marketing Competency Report,...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
